Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) closed the second and final tranche of a non-brokered private placement on Feb 18, 2026, issuing 390,000 Units at $1.00 each for $390,000. The Offering raised aggregate gross proceeds of $3.5 million via 3,500,000 Units.
Each Unit includes one common share and one-half warrant; each whole warrant is exercisable at $1.35 for two years. Post-closing, there are 92,223,699 common shares outstanding. Securities are subject to a four-month-and-one-day hold ending June 19, 2026, and are not registered in the United States.
NetraMark (AIAI / OTCQB: AINMF) announced it will uplist to the Toronto Stock Exchange. The Company will voluntarily delist from the Canadian Securities Exchange effective close of market Feb 17, 2026 and commence TSX trading at market open Feb 18, 2026 under symbol AIAI.
The Common Shares will remain listed on the OTCQB as AINMF and on the Frankfurt exchange as PF0. Shareholders are not required to take any action. Management said the TSX listing should enhance access to institutional investors and support commercial adoption of NetraAI.
NetraMark Holdings (OTCQB: AINMF; CSE: AIAI; Frankfurt: PF0) named Lawrence Guy to its Board of Directors on January 29, 2026.
Mr. Guy brings capital-markets and investment-management experience, a CFA designation, prior CFO and portfolio-management roles, and current directorships at multiple TSX-V issuers to support NetraMark’s growth and governance.
NetraMark (OTCQB: AINMF) closed the first tranche of a non-brokered private placement for $3,110,000 by issuing 3,110,000 Units at $1.00 each. Each Unit includes one common share and one-half warrant exercisable at $1.35 for two years. There are now 91,778,520 common shares outstanding. Insiders purchased 2,060,000 Units; the securities are subject to a 4-month-and-a-day hold expiring May 28, 2026. The company received commitments for a second tranche of $390,000 expected to close in the near term, and intends to use proceeds for working capital and general corporate purposes.
NetraMark (OTCQB: AINMF) retained LodeRock Advisors for strategic investor relations and capital markets communications services, effective January 22, 2026. The engagement includes a 12-month IR strategy, marketing schedule, investor targeting, outreach, non-deal roadshows coordination with investment dealers, and ongoing capital markets counsel.
Under the agreement NetraMark will pay LodeRock a monthly fee of CAD $11,000. Services continue until terminated by either party with 60 days’ written notice. No securities or ownership interest will be issued to LodeRock or its executives; the relationship is arm’s length.
NetraMark (OTCQB: AINMF) announced a non-brokered private placement of up to 3,500,000 units at $1.00 CDN per unit to raise up to $3.5M CDN. Each unit consists of one common share and one-half warrant; each whole warrant allows purchase of one share at $1.35 for two years from closing. Securities will be subject to a statutory 4-month plus 1 day hold under Canadian law and will not be registered in the United States. Net proceeds are intended for general working capital and advancement/commercialization of the NetraAI platform and support of biopharmaceutical engagements.
NetraMark (OTCQB: AINMF / CSE: AIAI) reported a transformational quarter with commercial, regulatory, and scientific milestones. Key items: contract backlog rose to C$2.5M; the company reiterated its target of C$8–10M backlog by mid‑2026. NetraMark completed a FDA Critical Path Innovation Meeting (CPIM) on NetraAI, received guidance on enrichment methodology and Type I error control, and was advised to consider the FDA MIDD paired meeting pathway. The company had a Nature Portfolio (npj Digital Medicine) study accepted (Dec 8, 2025) validating NetraAI in a Phase II depression trial. Commercially, Worldwide Clinical Trials onboarding finished in mid‑October, enabling inclusion in Phase 2/3 bids, and a CAMH collaboration secured an Ontario Research Fund award.
NetraMark (OTCQB: AINMF) and the Centre for Addiction and Mental Health announced on December 16, 2025 that they received an Ontario Research Fund - Research Excellence award to deploy NetraAI in CAMH’s secure HPC environment.
The project will analyze genetic and epigenetic data from schizophrenia and major depressive disorder studies to identify explainable patient subpopulations, support precision treatment strategies, and refine NetraAI for pharmaceutical clinical trials. Installation is led by CAMH Research IT with on-site NetraMark support; analyses will use de-identified data under CAMH privacy and security standards. The collaboration also includes evaluation of an OHIP administrative “bonus dataset” for cost-effectiveness and health-system impact analyses.
NetraMark (OTCQB: AINMF) announced completion of a Critical Path Innovation Meeting (CPIM) with FDA on December 15, 2025.
FDA provided scientific feedback on NetraAI's explainable AI/ML enrichment approach, recommended considering the MIDD Paired Meeting Program for further regulatory dialogue, and discussed potential applications including targeted inclusion/exclusion criteria, pre-specified stratification in the SAP, and trial simulations to assess power and robustness.
The company emphasized the CPIM's non-binding nature and said the discussion clarified regulatory considerations and potential pathways to support Phase 2/3 trial design.
NetraMark (OTCQB: AINMF) announced it was awarded a new contract from a global biopharmaceutical company to support analytics for a pivotal Phase 3 clinical trial, executed under an existing master services agreement on Dec 11, 2025. The engagement expands NetraMark’s role into late‑stage decision support using NetraAI to identify explainable patient subpopulations (responders, non‑responders, placebo‑associated) and analyze treatment and placebo‑response patterns.
The analytics aim to strengthen interpretation of trial outcomes across result scenarios and support clinical, regulatory, and commercial planning, reinforcing repeat business and growing adoption of NetraAI in Phase 3 programs.